Price T Rowe Associates Inc. MD increased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 12.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,343,643 shares of the company's stock after buying an additional 363,394 shares during the quarter. Price T Rowe Associates Inc. MD owned 5.23% of MoonLake Immunotherapeutics worth $181,059,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of MoonLake Immunotherapeutics by 96.2% in the third quarter. State Street Corp now owns 87,637 shares of the company's stock worth $4,419,000 after purchasing an additional 42,980 shares in the last quarter. Barclays PLC increased its stake in shares of MoonLake Immunotherapeutics by 1,269.2% in the third quarter. Barclays PLC now owns 5,641 shares of the company's stock worth $283,000 after acquiring an additional 5,229 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 2.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 79,648 shares of the company's stock worth $4,313,000 after acquiring an additional 2,180 shares in the last quarter. Congress Asset Management Co. boosted its position in MoonLake Immunotherapeutics by 9.5% during the fourth quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock valued at $3,953,000 after purchasing an additional 6,352 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in MoonLake Immunotherapeutics by 47.3% in the fourth quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company's stock valued at $6,018,000 after purchasing an additional 35,664 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.
MoonLake Immunotherapeutics Stock Performance
NASDAQ:MLTX opened at $39.42 on Friday. The firm's 50-day moving average is $38.67 and its 200-day moving average is $45.60. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $58.26. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -30.56 and a beta of 1.32.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on MLTX shares. Royal Bank of Canada started coverage on MoonLake Immunotherapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price target for the company. HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Needham & Company LLC increased their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group reduced their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of "Buy" and an average price target of $80.50.
Get Our Latest Report on MLTX
MoonLake Immunotherapeutics Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More
Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
